ESMO 2023 | ctDNA as prognostic biomarker in resected CRC: 24-mo DFS update from GALAXY (CIRCULATE-Japan)

Yoshiaki Nakamura, MD, PhD, National Cancer Center Hospital East, Kashiwa, Japan, shares an updated analysis of the GALAXY study focused on 2,280 patients with clinical stage II-IV colorectal cancer (CRC) who underwent postoperative ctDNA-based molecular residual disease (MRD) analysis. The study found that patients with ctDNA-positivity at the 4-week time point after surgery had significantly worse disease-free survival (DFS) compared to ctDNA-negative patients. Among patients with stage II-III CRC, those without MRD (N=1,333) had similar DFS whether they received adjuvant chemotherapy (ACT) or not, while MRD-positive patients (N=222) benefited significantly from ACT. Specifically, the 24-month DFS for MRD-positive patients who received ACT was 51.9% compared to those who did not experience disease recurrence. Further analysis revealed that MRD-positive patients who received 6 months of ACT had improved DFS compared to those who received 3 months. Overall, ctDNA status was the most significant prognostic factor for poor outcomes, emphasizing its predictive value in patient outcomes in this cohort of over 2,000 patients. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.